DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184

Abstract

Get full access to this article

View all access options for this article.

References

Seavey

Dobrzanski

. The many faces of Janus kinase. Biochem Pharmacol 2012; 83: 1136–1145.

Norman

. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs 2014; 23: 1067–1077.

Cacoub

Musette

Descamps

. The DRESS syndrome: A literature review. Am J Med 2011; 124: 588–597.

US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, et al. Guidance for Industry. Drug-induced liver injury: Premarketing clinical evaluation, http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf (2009, accessed October 2014).

XELJANZ. Highlights of prescribing information, http://labeling.pfizer.com/ShowLabeling.aspx?id=959 (2014, accessed October 2014).

US Food and Drug Administration, FDA background materials for new drug application 203214: Tofacitinib for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had inadequate response to one or more disease modifying anti-rheumatic drugs, http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM302958.pdf (2012, accessed October 2014).